EUVIMED · CrossrefZeitschrift
Expert Opinion on Drug Safety
ISSN 1474-0338 · Informa UK Limited
Neueste Artikel
A learning pharmacovigilance system for frail patients: integrating real-world data, artificial intelligence, clinical pharmacology and medicines optimization to prevent medication-related harm
Artificial intelligence–driven pharmacovigilance: transforming signal detection, real-world drug safety monitoring, and regulatory decision-making
A safety profile on idarucizumab for dabigatran reversal: an update
Long-term safety of etrasimod in ulcerative colitis: a narrative review
Momelotinib for the treatment of myelofibrosis in patients with moderate-to-severe anemia: a drug safety evaluation
Adverse events associated with obeticholic acid: a real-world, pharmacovigilance study
Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database
Cardiovascular adverse events associated with EGFR and HER2 dual TKIs: a pharmacovigilance study based on the FAERS database
Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implications
Drug-induced Guillain-Barré Syndrome: a disproportionality analysis based on the US FDA adverse event reporting system
Pancreatic adverse events induced by immune checkpoint inhibitors: a real-world observational study
Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database
A disproportionality analysis of interstitial lung disease associated with drug therapy in spontaneous adverse event reports
Infection-related adverse events comparison of bortezomib, carfilzomib and ixazomib: a pharmacovigilance study based on FAERS
Safety and effectiveness of empagliflozin in Japanese patients with heart failure: a 1-year post-marketing surveillance study stratified by age
Pharmacovigilance insights into antibody–drug conjugates: a multi-database analysis of adverse events in leukemia treatment
Trends in the use of sodium-glucose cotransporter-2 inhibitors and characteristics of adverse event reporting in patients with heart failure in Japan: reports from the medical administration database and the adverse event reporting database
Analysis of risk factors and development of a predictive model for significant serum creatinine elevation in patients administered SGLT2 inhibitor in a real-world clinical setting in China
Angioedema risk of thrombolytics: an integrated assessment using disproportionality analysis of the USFDA adverse event reporting system, case reviews and meta-analysis
The effectiveness and safety of naldemedine in treating opioid-induced constipation among non-cancer adult patients: updated meta-analysis
Dipyridamole-associated pulmonary edema: discovery of a new potential adverse reaction signal based on the FAERS database
Biologic and targeted synthetic therapies in juvenile idiopathic arthritis: a review of current and emerging therapeutic agents
GLP-1-derived therapies and risk of sarcopenia: myth or reality?
Cardiorenometabolic medicine as a new subspecialty in the light of novel pharmaceuticals with dual or triple benefits
Safety and efficacy of currently used drug therapies for treatment of lymphomas in patients with Sjögren’s disease, a scoping review
A look into adverse renal effects of proton pump inhibitors
GLP-1 receptor agonists in older people with type 2 diabetes: safety evidence from the real world
Early recognition, prevention, and management of glucocorticoid toxicity in patients with rheumatic diseases
Safety evaluation of ILaris: a real-world analysis of adverse events based on the FAERS database
Assessment of Riociguat-related adverse events: a disproportionality analysis utilizing the FDA adverse event reporting system database
EUVIMED